KUGLÍK, Petr, Vladimíra VRANOVÁ, Dita ŽEŽULKOVÁ, Lenka ŠTEFANČÍKOVÁ, Eva NEČESALOVÁ, Hana FILKOVÁ, Alexandra OLTOVÁ, Pavel MAZÁNEK and Jaroslav ŠTĚRBA. High-resolution of comparative genomic hybridization improves detection of chromosomal aberrations with prognostic significance in neuroblastoma. In Europen Journal of Human Genetics. Amsterdam: ESHG, 2006, p. 184. ISSN 1018-4813.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name High-resolution of comparative genomic hybridization improves detection of chromosomal aberrations with prognostic significance in neuroblastoma
Name in Czech Použití techniky komparativní genomové hybridizace s vysokým rozlišením (HR-CGH) zlepšuje detekci chromozomových aberací s prognostickým významem u neuroblastomu
Authors KUGLÍK, Petr (203 Czech Republic, guarantor), Vladimíra VRANOVÁ (703 Slovakia), Dita ŽEŽULKOVÁ (203 Czech Republic), Lenka ŠTEFANČÍKOVÁ (203 Czech Republic), Eva NEČESALOVÁ (203 Czech Republic), Hana FILKOVÁ (203 Czech Republic), Alexandra OLTOVÁ (203 Czech Republic), Pavel MAZÁNEK (203 Czech Republic) and Jaroslav ŠTĚRBA (203 Czech Republic).
Edition Amsterdam, Europen Journal of Human Genetics, p. 184-184, 2006.
Publisher ESHG
Other information
Original language English
Type of outcome Proceedings paper
Field of Study Genetics and molecular biology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.697
RIV identification code RIV/00216224:14310/06:00017834
Organization unit Faculty of Science
ISSN 1018-4813
Keywords in English neuroblastoma; high resolution comparative genomic hybridization; chromosomal aberration; prognostic factors
Tags chromosomal aberration, neuroblastoma, prognostic factors
Changed by Changed by: doc. RNDr. Petr Kuglík, CSc., učo 1881. Changed: 9/4/2010 10:31.
Abstract
Neuroblastoma (NB) is a genetically very heterogeneous pediatric malignant tumor. The clinical course of NB vary markedly. Therefore molecular and cytogenetic markers are studied as strong predictors of clinical outcome, to amnedclinical staging and aid in treatment planning. This malignancy is characterized by a broad spectrum of clinical behavior. Low-, intermediate, and high-risk groups have been defined based upon expected outcome following conventional therapy using both clinical and biological criteria. The criteria currently used to assign risk-group are as follows: Clinical stage, MYCN status, Shimada histology and DNA ploidy. Recently, other cytogenetic changes as 1p, 3p, 11q deletions and 17q rearrangements may also have prognostic value. The are a number of molecular genetic features known which are of prognostic importance in neuroblastoma - expression of different molecular markers as neurotrophin tyrosin kinase receptors (TrkA, B and C), tyrosine hydroxylase, neuroendocrine protein gene product 9,5 (PGP9,5), telomerase reverse transcriptase (hTERT) and vascular endothelial growth factor-A (VEGF-A). Some of them are already candidates stratifying markers. A global view of cytogenetic imbalances in NB patients can be detected by CGH. With recently developed high resolution (HR-CGH) method, we can find aberrations of < 10 Mb. In this study we report about the application of FISH and CGH/HR-CGH method for the detection of chromosomal imbalances in NB patients. In our work, FISH technique and CGH analyses were applied to 49 neuroblastomas of both low and high stage disease and the data were reviewed and correlated with clinical characteristics, including survival analysis.
Abstract (in Czech)
Práce se zabývá využitím techniky komparativní genomé hybridizace s vysokým rozlišením (HR-CGH) při vyšetření cytogenetických změn s prognostickým významem u pacientů s neuroblastomem léčených na KDO FN Brno.
Links
MSM0021622415, plan (intention)Name: Molekulární podstata buněčných a tkáňových regulací
Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations
NR9125, research and development projectName: Diagnostický a prediktivní význam molekulárně cytogenetických markerů u embryonálních nádorů dětského věku.
Investor: Ministry of Health of the CR
PrintDisplayed: 28/8/2024 02:54